Guangdong Biolight Meditech Co., Ltd. Class A

Guangdong Biolight Meditech Co., Ltd. Class A

SSZSE:300246
12.56
CNY
-0.27
(-2.10%)
-0.45EPS
4.09BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A carries a market capitalization of 4.09B, placing it among publicly traded companies globally. Its enterprise value stands at 4.27B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.09B
Enterprise Value4.27B

Important Dates

Guangdong Biolight Meditech Co., Ltd. Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A has 264.76M shares outstanding.

Shares Outstanding264.76M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 3.64, and the price-to-book ratio stands at 3.78.

PS Ratio3.64
PB Ratio3.78
P/TBV Ratio4.27

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 3.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.27B versus a market cap of 4.09B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.82

Financial Position

As of September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A maintains a current ratio of 1.50, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.96, indicating elevated leverage, while an interest coverage ratio of -2.17 demonstrates limited ability to service its debt obligations.

Current Ratio1.50
Quick Ratio0.53
Debt / Equity42.96
Debt / EBITDA-4.39
Interest Coverage-2.17

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A posted a negative return on equity (ROE) of -10.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.95, reflecting losses generated across the asset base. The company generates approximately 900,027.33 in revenue per employee across its workforce of 1,242.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.07 indicates how many times Guangdong Biolight Meditech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-10.20
Return on Assets (ROA)-4.95
Revenue Per Employee900,027.33
Employee Count1,242.00
Inventory Turnover3.07

Taxes

CNY

Over the twelve months ended September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A recorded an income tax benefit of -15.25M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -133.31M and -117.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-15.25M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Guangdong Biolight Meditech Co., Ltd. Class A's stock has gained approximately 36.52% over the past 52 weeks. The 50-day moving average sits at 13.98, while the 200-day moving average is 15.29.

52-Week Price Change36.52%
50-Day Moving Average13.98
200-Day Moving Average15.29

Income Statement

CNY

Over the twelve months ended September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A generated 1.12B in revenue and converted that into -117.61M in net income, yielding earnings per share of -0.45. EBITDA reached -113.08M, while operating income came in at -22.67M.

Revenue1.12B
Gross Profit268.99M
Operating Income-22.67M
Pretax Income-133.31M
Net Income-117.61M
EBITDA-113.08M
EBIT-113.08M
Earnings Per Share (EPS)-0.45

Balance Sheet

CNY

As of September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A holds 388.72M in cash and equivalents against 496.75M in total debt, resulting in a net debt position of 13.56M. Total book value stands at 1.08B, with working capital of 359.78M providing operational flexibility.

Cash & Cash Equivalents388.72M
Total Debt496.75M
Net Debt13.56M
Equity (Book Value)1.08B
Book Value Per Share4.09
Working Capital359.78M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-115.83M

Margins

Over the twelve months ended September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A posted a gross margin of 24.06, reflecting its pricing power and cost economics. The operating margin of -2.03 and net profit margin of -10.52 provide insight into operational efficiency.

Gross Margin24.06
Operating Margin-2.03
Pretax Margin-11.93
Profit Margin-10.52
EBITDA Margin-10.12

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A paid dividends of 0.22 per share. The dividend payout ratio of -48.47 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 6.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Guangdong Biolight Meditech Co., Ltd. Class A shareholders.

Dividend Per Share0.22
Payout Ratio-48.47
Shareholder Yield6.18

Stock Splits

Guangdong Biolight Meditech Co., Ltd. Class A's most recent stock split took place on May 25, 2023 with a 2:3 split ratio.

Last Split Date5/25/2023
Split Ratio2:3

Scores

As of September 30, 2026, Guangdong Biolight Meditech Co., Ltd. Class A has an Altman Z-Score of 2.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.92